Skip to main content

Table 2 Patients' parameters immediately prior to treatment initiation

From: Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial

 

rhTM group (n = 10)

Untreated group (n = 13)

Normal range

p

PaO2/FiO2 ratio

168 ± 56

183 ± 47

N.A

0.5

CRP (mg/dl)

11.5 ± 8.3

11.0 ± 11.1

<0.03

0.6

LDH (IU/l)

378 ± 118

444 ± 173

120–240

0.4

KL-6 (U/ml)

1512 ± 583

2060 ± 1520

<500

0.8

SP-D (ng/ml)

482 ± 527

676 ± 711

<110

0.2

D-dimer (μg/ml)

5.3 ± 7.9

6.9 ± 8.9

<0.5

0.5

TAT (ng/ml)

8.1 ± 13.5

N.D

<3.0

 

PIC (μg/ml)

3.0 ± 5.1

N.D

<0.8

 

PAI-1 (ng/ml)

59.0 ± 52.4

N.D

≦50

 

ProteinC (%)

84.7 ± 25.1

N.D

64–135

 

ATIII (%)

90.9 ± 15.1

N.D

83 × 128

 

HMGB1 (ng/ml)

10.6 ± 4.7

N.D

N.A

 

Thrombomodulin (U/ml)

16.1 ± 5.9

N.D

12.1–24.9

 
  1. Data are expressed as the mean ± standard deviation
  2. p: rhTM group vs. untreated group
  3. N.D. no data, N.A. not available
  4. AE-IPF acute exacerbation of idiopathic pulmonary fibrosis, rhTM recombinant human soluble thrombomodulin, CRP C-reactive protein, LDH lactate dehydrogenase, KL-6 Krebs von der lungen-6, SP-D surfactant protein D, TAT thrombin–antithrombin complex, PIC plasmin-α2 plasmin inhibitor complex, PAI-1 plasminogen activator inhibitor-1, AT III antithrombin III, HMGB1 high mobility group box 1
Back to article page

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us